Samsung just turned its Galaxy Buds into FDA-cleared medical devices. The company announced today that its Galaxy Buds3 Pro and upcoming Buds4 Pro can now function as over-the-counter hearing aids for adults with mild to moderate hearing loss - no prescription or audiologist visit required. It's a move that puts Samsung squarely in competition with traditional hearing aid manufacturers and mirrors Apple's similar push into hearing health.
Samsung just made a serious play in the hearing health market. The company announced today that its Galaxy Buds Hearing Aid feature has cleared FDA review, transforming compatible earbuds into over-the-counter medical devices. Starting Q4 2026, Galaxy Buds3 Pro and the upcoming Buds4 Pro will offer clinical-grade hearing support without the traditional barriers of cost, stigma, or audiologist appointments.
The timing couldn't be more strategic. According to the World Health Organization, more than 1.5 billion people worldwide experience some degree of hearing loss - a figure expected to balloon to 2.5 billion by 2050. Yet adoption of traditional hearing aids remains stubbornly low, held back by price tags that can hit thousands of dollars and the hassle of clinical fittings.
"Hearing health is a vital component of our overall well-being, profoundly impacting how we communicate, connect with loved ones and engage with the world," Hon Pak, Senior Vice President and Head of the Digital Health Team at Samsung's Mobile eXperience Business, told Samsung Newsroom. "With the latest clearance from the FDA, we're expanding access to hearing support and making proactive care effortless."
Samsung's approach centers on two integrated features built directly into Galaxy Buds - no separate app downloads required. Users navigate to the Galaxy Buds menu in Settings to complete a self-administered Hearing Test in about five minutes. The software uses clinical-grade pure-tone audiometry, testing each ear individually to map specific hearing deficits. It generates an audiogram that Samsung claims matches professional audiologist evaluations in accuracy, categorizing hearing as normal or ranging through mild, moderate, severe, or profound loss.
The Hearing Test itself is registered as Software as a Medical Device (SaMD), giving it medical-grade credibility. Once users have their results, the Hearing Aid feature kicks in, amplifying sounds they struggle to hear - high frequencies, distant voices, surrounding whispers - all personalized to their unique hearing profile.
But Samsung isn't just slapping amplification onto consumer earbuds and calling it medical. The company collaborated with the National Acoustic Laboratories and Samsung Medical Center to develop the technology, which uses NAL-NL2 - the globally recognized clinical standard for fitting prescription hearing aids. Clinical validation studies at Vanderbilt University Medical Center, San Jose State University, and the University of Memphis back the tech.
The Hearing Aid feature also packs advanced capabilities typically found in premium hearing aids: noise elimination and beamforming technology that focuses sound in front of the user while suppressing background noise. These aren't trivial features - they're what separate functional hearing aids from simple amplifiers.
Samsung has been building toward this moment since 2020, when it introduced a Personal Sound Amplification Product feature on Galaxy Buds+. That PSAP feature was clinically validated in 2021 as effective for daily communication support, laying the groundwork for this FDA-cleared iteration.
The move puts Samsung in direct competition with Apple, which launched similar hearing aid functionality for AirPods Pro 2 in 2024. It also challenges traditional hearing aid manufacturers like Sonova, Demant, and WS Audiology, whose devices typically cost $1,000 to $6,000 per pair.
Samsung's hearing-related insights - including noise exposure levels and Hearing Test results - sync directly to the Samsung Health app, giving users a unified view of their wellness data. Full support requires a compatible Galaxy device running One UI 8 or later.
The FDA clearance specifically covers users 18 and older with perceived mild to moderate hearing loss. Samsung is careful to note the feature "is not a substitute for professional diagnosis or treatment by a qualified clinician" - standard regulatory language that protects both the company and users who may need more comprehensive care.
Availability will roll out in Q4 2026 across the U.S. and select approved markets. Pricing for Galaxy Buds3 Pro and Buds4 Pro hasn't been disclosed, but Samsung's previous Galaxy Buds Pro models typically retail between $200-$250 - a fraction of traditional hearing aid costs.
Samsung's FDA clearance represents a significant shift in how consumer tech companies approach healthcare. By embedding medical-grade hearing support directly into mainstream earbuds, Samsung is betting it can crack a market that's remained frustratingly inaccessible to millions who need it. The real test will be whether users trust their $200 earbuds to handle what traditional $3,000 hearing aids do - and whether insurance companies and healthcare providers eventually recognize these OTC solutions as legitimate alternatives. With the WHO projecting hearing loss to affect 2.5 billion people by 2050, Samsung and Apple are positioning themselves at the front of what could become a massive healthcare disruption.
